Association of XPC polymorphisms with susceptibility and clinical outcome to chemotherapy in breast cancer patients

Cancer Science

Volumn 103, Issue 7, 2012, Pages 1207-1214

  Yang, Xiuli ^a   Liu, Duo ^a   Wu, Huizhe ^a   Kang, Hui ^a   Pang, Hao ^a   Huang, Desheng ^a   Sha, Xianzheng ^a   Wang, Enhua ^a   Wang, Zhe ^a   Wei, Minjie ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BRCA1 PROTEIN; PROTEIN P53; XERODERMA PIGMENTOSUM GROUP C PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SUSCEPTIBILITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE NEU; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AMINO ACID SUBSTITUTION; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; ODDS RATIO; OUTCOME ASSESSMENT (HEALTH CARE); POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS;

EID: 84863329375     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02312.x     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000; 92: 874-97.
3. Ramos JM, Ruiz A, Colen R, Lopez ID, Grossman L, Matta JL. DNA repair and breast carcinoma susceptibility in women. Cancer 2004; 100: 1352-7.
4. Jorgensen TJ, Visvanathan K, Ruczinski I, Thuita L, Hoffman S, Helzlsouer KJ. Breast cancer risk is not associated with polymorphic forms of xeroderma pigmentosum genes in a cohort of women from Washington County, Maryland. Breast Cancer Res Treat 2007; 101: 65-71.
5. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 1513-30.
6. Yang ZH, Liang WB, Jia J, Wei YS, Zhou B, Zhang L. The xeroderma pigmentosum group C gene polymorphisms and genetic susceptibility of nasopharyngeal carcinoma. Acta Oncol 2008; 47: 379-84.
7. Lockett KL, Snowhite IV, Hu JJ. Nucleotide-excision repair and prostate cancer risk. Cancer Lett 2005; 220: 125-35.
8. Sugasawa K, Shimizu Y, Iwai S, Hanaoka F. A molecular mechanism for DNA damage recognition by the xeroderma pigmentosum group C protein complex. DNA Repair 2002; 1: 95-107.
9. Araki M, Masutani C, Takemura M. Centrosome protein centrin 2/caltractin 1 is part of the xeroderma pigmentosum group C complex that initiates global genome nucleotide excision repair. J Biol Chem 2001; 276: 18665-72.
10. Smith TR, Levine EA, Freimanis RI et al. Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. Carcinogenesis 2008; 29: 2132-8.
11. Shen J, Desai M, Agrawal M et al. Polymorphisms in nucleotide excision repair genes and DNA repair capacity phenotype in sisters discordant for breast cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 1614-9.
12. Försti A, Angelini S, Festa F et al. Single nucleotide polymorphisms in breast cancer. Oncol Rep 2004; 11: 917-22.
13. Zheng W, Cong XF, Cai WH, Yang S, Mao C, Zou HW. Current evidences on XPC polymorphisms and breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 2011; 128: 811-5.
14. Zhang L, Zhang Z, Yan W. Single nucleotide polymorphisms for DNA repair genes in breast cancer patients. Clin Chim Acta 2005; 359: 150-5.
15. Hu Z, Wang Y, Wang X et al. DNA repair gene XPC genotypes/haplotypes and risk of lung cancer in a Chinese population. Int J Cancer 2005; 115: 478-83.
16. Shen M, Berndt SI, Rothman N et al. Polymorphisms in the DNA nucleotide excision repair genes and lung cancer risk in Xuan Wei, China. Int J Cancer 2005; 116: 768-73.
17. Lee GY, Jang JS, Lee SY et al. XPC polymorphisms and lung cancer risk. Int J Cancer 2005; 115: 807-13.
18. Marin MS, Lopez-Cima MF, Garcia-Castro L, Pascual T, Marron MG, Tardon A. Poly (AT) polymorphism in intron 11 of the XPC DNA repair gene enhances the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 1788-93.
19. Vogel U, Overvad K, Wallin H, Tjonneland A, Nexo BA, Raaschou-Nielsen O. Combinations of polymorphisms in XPD, XPC and XPA in relation to risk of lung cancer. Cancer Lett 2005; 222: 67-74.
20. Yun Bai, Liang Xu, Xiaobo Yang et al. Sequence variations in DNA repair gene XPC is associated with lung cancer risk in a Chinese population: a case-control study. BMC Cancer 2007; 7: 81.
21. Dong J, Hu Z, Shu Y et al. Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis. Mol Carcinog 2011; doi: 10.1002/mc.20819. [Epub ahead of print].
22. Sak SC, Barrett JH, Paul AB, Bishop DT, Kiltie AE. The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder. Br J Cancer 2005; 92: 2262-5.
23. García-Closas M, Malats N, Real FX et al. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 536-42.
24. Sak SC, Barrett JH, Paul AB, Bishop DT, Kiltie AE. Comprehensive analysis of 22 XPC polymorphisms and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 2537-41.
25. Yimin Zhu, Maode Lai, Hushan Yang et al. Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. Carcinogenesis 2007; 28: 698-703.
26. Yang M, Kang MJ, Choi Y et al. Associations between XPC expression, genotype, and the risk of head and neck cancer. Environ Mol Mutagen 2005; 45: 374-9.
27. Sugimura T, Kumimoto H, Tohnai I et al. Gene-environment interaction involved in oral carcinogenesis: molecular epidemiological study for metabolic and DNA repair gene polymorphisms. J Oral Pathol Med 2006; 35: 11-8.
28. Kietthubthew S, Sriplung H, Au WW, Ishida T. Polymorphism in DNA repair genes and oral squamous cell carcinoma in Thailand. Int J Hyg Environ Health 2006; 209: 21-9.
29. Ye W, Kumar R, Bacova G, Lagergren J, Hemminki K, Nyren O. The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case-control study in Sweden. Carcinogenesis 2006; 27: 1835-41.
30. Weiss JM, Weiss NS, Ulrich CM, Doherty JA, Voigt LF, Chen C. Interindividual variation in nucleotide excision repair genes and risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2524-30.
31. Huang WY, Berndt SI, Kang D et al. Nucleotide excision repair gene polymorphisms and risk of advanced colorectal adenoma: XPC polymorphisms modify smoking-related risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 306-11.
32. Hirata H, Hinoda Y, Tanaka Y et al. Polymorphisms of DNA repair genes are risk factors for prostate cancer. Eur J Cancer 2007; 43: 231-7.
33. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-66.
34. Guo W, Zhou RM, Wan LL et al. Polymorphisms of the DNA repair gene xeroderma pigmentosum groups A and C and risk of esophageal squamous cell carcinoma in a population of high incidence region of North China. J Cancer Res Clin Oncol 2008; 134: 263-70.
35. Kusumoto R, Masutani C, Sugasawa K et al. Diversity of the damage recognition step in the global genomic nucleotide excision repair in vitro. Mutat Res 2001; 485: 219-27.
36. Yokoi M, Masutani C, Maekawa T, Sugasawa K, Ohkuma Y, Hanaoka F. The xeroderma pigmentosum group C protein complex XPC-HR23B plays an important role in the recruitment of transcription factor IIH to damaged DNA. J Biol Chem 2000; 275: 9870-5.
37. Giaccone G, Pinedo HM. Drug resistance. Oncologist 1996; 1: 82-7.
38. Fleming ND, Agadjanian H, Nassanian H et al. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer. Cancer 2012; 118: 689-97.
39. Chen F, Wang W, El-Deiry WS. Current strategies to target p53 in cancer. Biochem Pharmacol 2010; 80: 724-30.
40. Zhang XP, Liu F, Wang W. Two-phase dynamics of p53 in the DNA damage response. Proc Natl Acad Sci USA 2011; 108: 8990-5.